EntreMed (ENMD +8%) gets a pop today after announcing earlier that it has initiated a second...
EntreMed (ENMD +8%) gets a pop today after announcing earlier that it has initiated a second site at Indiana University for its Phase 2 study of ENMD-2076 in triple-negative breast cancer. Initial studies, supported by a grant from the National Cancer Institute, are already underway at the University of Colorado Cancer Center.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs